Trial · NCT06787846
EFFICACY and TOLERABILITY of TESTED FORMULA VS. HYDROQUINONE 4% in the TREATMENT of FACIAL MELASMA
NCT06787846, Not applicable, Completed, Cosmetique Active International
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. EFFICACY and TOLERABILITY of TESTED FORMULA VS. HYDROQUINONE 4% in the TREATMENT of FACIAL MELASMA. Trials, record NCT06787846. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06787846
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- EFFICACY and TOLERABILITY of TESTED FORMULA VS. HYDROQUINONE 4% in the TREATMENT of FACIAL MELASMA
- NCT number
- NCT06787846
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 109 participants, actual
- Lead sponsor
- Cosmetique Active International
- Conditions
- Melasma
- Interventions
- Experimental: Group TP, Active Comparator: Group HQ: Hydroquinone 4%
- First posted
- 2025-01-22
- Last updated
- 2025-01-22
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in mMASI scoring | From baseline to 3months | The mMASI is calculated using 3 components: four regions of the face (forehead, right malar, left malar and chin); area of involvement for each region (using a scale from 0 to 6): darkness compared to the surrounding normal skin for each area (evaluated using a scale from 0 to 4). |
| Primary | Evaluation of Global Tolerance | From 1month to 3 months | The investigator evaluates the tolerance using a 5-point skin reaction scale (0 represent No local intolerance ; 4 represent a Very severe signs or symptoms of intolerance) |
| Secondary | Change in Investigator's Global Assessment (IGA) | From baseline to3 months | The investigator evaluates the severity of melasma using a 4-point scale (from 0 (cleared, almost cleared) to 3 (severe (markedly darker than the surrounding normal skin)). |
| Secondary | Change in Subject Global Assessment of Improvement (SGAI) | From 1month to 3 months | The subject evaluates the change on a 6-point scale from -1 (worsened) to 4 (totally cleared). |
| Secondary | Change of Quality of life | From 1month to 3 months | Subjects evaluate about the impact of melasma on the quality of life. On a scale of 1 (not bothered at all) to 7 (bothered all the time), the subject's rate how they feel. MELAS Qol scores range from 7 to 70, with a higher score signifying worse quality of life. |
| Secondary | Change of stigmatization evaluation | From 1month to 3 months | Subjects evaluate about the impact of melasma on stigmatization evaluation. On a scale of 1 (not bothered at all) to 7 (bothered all the time), the subject's rate how they feel. MELAS Qol scores range from 7 to 70, with a higher score signifying worse quality of life. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40586974 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06787846
GET https://conductscience.org/api/trials/v1/NCT06787846/registered